Industry · Biotech

Advanced therapies deserve an early, expert strategy on both sides.

Taking innovative medicines abroad: from FDA IND / EU CTA to clinical development and market authorisation in Europe and the US.

Biologics, cell and gene therapies, RNA and other novel modalities, with early regulatory dialogue, evidence-gap assessment and clinical development planning.

FocusBiologics · ATMPs · RNA
Early planningOrphan · PRIME eligibility · Paediatric plans
CommitteesCHMP · CAT · COMP
Overview

Both regulators engage early with innovation, provided you ask the right way.

EMA offers scientific advice, protocol assistance and product-specific programmes. Orphan designation, PRIME eligibility, paediatric investigation plans and ATMP classification have distinct purposes and criteria. Biotechnology-derived biosimilars use the mandatory centralised route.

Kaiveo Medical helps Chinese biotech companies prepare agency questions, assess evidence gaps and plan global development through founder-led coordination. For drug-led combination products, the medicines pathway leads, with device-component requirements assessed as applicable. Specialist manufacturing and supply-chain needs are scoped with your team.

Challenges we solve

Early EMA dialogue

Scientific advice and protocol assistance strategy, briefing books, rehearsals and follow-up.

Regulatory programme assessment

Orphan designation, PRIME eligibility, ATMP classification and paediatric-plan requirements assessed for the product and development stage.

European clinical development

Global study design, country and site feasibility, and start-up coordination with Regulatory Affairs for CTA/IND dossiers.

CMC & GMP for complex products

Assessment of comparability, applicable GMP and supply-chain requirements with your CMC and quality teams.

Partnering & licensing support

Regulatory and clinical due-diligence packages for European licensing conversations.

Evidence for access

Early assessment of HTA and payer evidence questions to inform development planning.

How we support biotech clients

The same product, two regulators

Approval in one market does not carry over to the other. The relevance and sufficiency of existing evidence must be assessed for each intended route.

In Europe

  • EMA scientific advice and protocol assistance
  • PRIME eligibility, orphan designation and ATMP classification
  • Paediatric investigation plans
  • ATMP-specific GMP and comparability expectations
  • Committee interactions: CHMP, CAT and COMP
  • Assessment of trial legal-representation requirements
  • Assessment of QP and QPPV requirements; separate appointments

In the United States

  • Pre-IND and Type B / Type C meetings with FDA
  • Fast Track, Breakthrough Therapy and RMAT designation
  • Orphan drug designation and paediatric study plans
  • Product-specific IND and NDA / BLA pathway assessment
  • CBER interactions and INTERACT meetings

A typical biotech pathway

Regulatory positioning

Product classification, programme eligibility and global evidence needs assessed.

Scientific advice

Key CMC, non-clinical and clinical questions put to EMA with well-argued positions.

European clinical programme

Study planning, site and CRO assessment, and start-up coordinated with the regulatory dossier work.

MAA & launch

Marketing-application planning, agency interactions and launch-requirement assessment; outcomes depend on regulatory review.

Frequently asked

Our product is approved in China. Can we go straight to an MAA in Europe?
This depends on the product, data quality, GCP compliance and relevance to the intended population and clinical practice. We assess the package case by case; additional studies or scientific advice may be needed.
How does ATMP regulation differ from other biologics in Europe?
ATMPs are assessed by the Committee for Advanced Therapies with specific GMP, traceability, long-term follow-up and hospital-exemption considerations. We plan for these from the outset.
Can you support a European licensing partner search?
We can prepare the regulatory and clinical elements of a partnering package within an agreed scope. Partner-search or transaction services require separately confirmed specialist arrangements.

For partnering conversations

BD/licensing-ready regulatory package: a partner-ready summary of your EU/US regulatory position for out-licensing talks.

Biotech

Give your science the European strategy it deserves.

Early conversations make the biggest difference. Let's have one.

We aim to reply within two working days. Language support is agreed for each engagement.